Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Trial Profile

A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vebicorvir (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Assembly Biosciences

Most Recent Events

  • 15 Nov 2021 Results assessing changes in HBV nucleic acids in patients who continued NrtI treatment following discontinuation of Vebicorvir, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
  • 26 Jun 2021 Results assessing whether any treatment emergent core inhibitor or NrtI substitutions were observed after treatment discontinuation from study 211, presented at The International Liver Congress 2021.
  • 26 Jun 2021 Results assessing off-treatment (off-Rx) viral response and safety after VBR + NrtI discontinuation (DC) in Study 211, presented at The International Liver Congress 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top